Země: Kanada
Jazyk: angličtina
Zdroj: Health Canada
PINDOLOL
PRO DOC LIMITEE
C07AA03
PINDOLOL
10MG
TABLET
PINDOLOL 10MG
ORAL
100/300
Prescription
BETA-ADRENERGIC BLOCKING AGENTS
Active ingredient group (AIG) number: 0112362003; AHFS:
CANCELLED POST MARKET
2020-03-09
PRODUCT MONOGRAPH Pr PINDOLOL – 5 Pr PINDOLOL – 10 (Pindolol tablets U.S.P.) Tablets 5 and 10 mg Antihypertensive/Antianginal Agent PRO DOC LTÉE 2925, boul. Industriel Laval, Quebec H7L 3W9 CONTROL NO: 180570 DATE OF REVISION: December 19, 2014 NAME OF DRUG Pr PINDOLOL – 5 Pr PINDOLOL – 10 (Pindolol tablets U.S.P.) Tablets 5, and 10 mg THERAPEUTIC CLASSIFICATION Antihypertensive/Antianginal Agent ACTIONS PINDOLOL (pindolol) is a beta-adrenergic-receptor blocking agent which possesses partial agonist activity (intrinsic sympathomimetic activity-I.S.A). It is used in the treatment of hypertension and/or the prophylaxis of angina pectoris. Hypertension: The mechanism of the antihypertensive effects of pindolol has not been established. Among the factors that may be involved are: (a) Competitive ability to antagonize catecholamine-induced tachycardia at the beta- receptor sites in the heart, thus decreasing cardiac output. (b) A reduction in total peripheral resistance. (c) An inhibition of the vasomotor centres. (d) Inhibition of renin release by the kidneys. Angina Pectoris: The mechanism of the antianginal effect of pindolol has not been established. Pindolol may reduce the oxygen requirement of the heart at any level of effort by blocking catecholamine- induced increases in the heart rate, systolic blood pressure, and the velocity and extent of myocardial contraction. However, oxygen requirements may be increased by such actions as increases in left ventricular fibre length, end diastolic pressure and systolic ejection period. When the net effect is beneficial in anginal patients, it manifests itself during exercise or stress by delaying the onset of pain and reducing the incidence and severity of anginal attacks. Inman, orally-administered pindolol is rapidly and almost completely absorbed (≥95%) from the gastrointestinal tract. The mean absolute bioavailability after oral administration is about 87- 92%. Plasma levels of 10 to 30 nanogram/mL are associated with its therapeutic efficacy. Following sin Přečtěte si celý dokument